Drug Trial Radar · NCT06088199
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Oct 24, 2023
Primary completion
Aug 12, 2026
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
ApremilastDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse EventsTime frame: Day 1 up to approximately 285 days
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Affiliated Dermatology
Scottsdale, Arizona
Clear Dermatology
Scottsdale, Arizona
Johnson Dermatology Clinic
Fort Smith, Arkansas
Avance Clinical Trials
Laguna Niguel, California
University of California Irvine
Orange, California
MedDerm Associates
San Diego, California
Clinical Science Institute
Santa Monica, California
California Dermatology Institute
Thousand Oaks, California
Pediatric Skin Research LLC
Coral Gables, Florida
Ciocca Dermatology
Miami, Florida
University of South Florida
Tampa, Florida
Endeavor Health Clinical Trials Center
Skokie, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Southern Indiana Clinical Trials
New Albany, Indiana
Great Lakes Research Group Inc- Sheffield
Bay City, Michigan
Henry Ford Medical Center - New Center One
Detroit, Michigan
Dermatology and Skin Cancer Center of Lees Summit
Lee's Summit, Missouri
Boeson Research
Missoula, Montana
Empire Dermatology
East Syracuse, New York
State University of New York, Downstate Medical Center
Manhasset, New York
OptiSkin Medical
New York, New York
Hightower Clinical LLC
Oklahoma City, Oklahoma
Dermatology Research Center of Oklahoma, PLLC
Tulsa, Oklahoma
Oregon Health and Science University
Portland, Oregon
Medical University of South Carolina
Charleston, South Carolina
Studies in Dermatology LLC
Cypress, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
Stride Clinical Research LLC
Sugar Land, Texas
Frontier Derm Partners
Mill Creek, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.